Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.

The sera of 73 patients with nasopharyngeal carcinoma (NPC), 28 patients with other carcinomas (OC) and 89 healthy subjects (HS) were tested for IgG and IgA antibodies to Epstein-Barr virus (EBV) viral capsid antigen (VCA). The majority of the NPC sera had IgG titres of 160 or above, whereas the majority of the other sera had titres below 160. For IgA reactivity to EBV-VCA, 68 of 73 (93-2%) NPC sera had titres of greater than or equal to 10. In contrast, only 6 of 28 (21-4%) OC sera and none of the HS sera had such titres. The mean serum concentrations of IgG, IgA, IgM and C3' were also determined in 55 NPC and 20 OC patients and 18 HS. They were all significantly higher in the NPC sera than in the HS. Although the concentrations of IgG and C3' were not significantly different in the two carcinoma groups, the concentrations of IgA and IgM were significantly higher in the NPC group than in OC. These findings appear to reflect the intensity of EBV-specific antigenic stimulation in NPC, and the EBV-specific serum IgA reactivity may be a sueful aid to the diagnosis of NPC, especially in cases with an occult primary tumour. It may be also of value as a screening test in people at high risk.     

Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia

Antibody titers to Epstein-Barr virus (EBV)-associated early antigens (EA) and the viral capsid antigen (VCA) were determined by ELISA on 263 sera obtained from healthy donors, patients with Hodgkin's disease (HD), non-Hodgkin lymphomas (NHL), infectious mononucleosis (IM), Burkitt's lymphoma (BL), and nasopharyngeal carcinoma (NPC). As expected, most lymphoma patients showed markedly elevated anti-VCA IgG and anti-EA IgG antibody titers. Only one patient in the NHL group (n = 56) consisting of patients with lymphomas other than chronic lymphocytic leukemia (CLL) and hairy-cell leukemia (HCL), and 3 patients with HCL (n = 19) had high antibody titers of the IgA class to VCA and EA. Seventeen out of 48 patients (36%) with CLL had high IgA anti-VCA titers and 10 of these sera (21%) also contained IgA anti-EA. The geometric mean titer (GMT) of IgA anti-VCA was 2,510, the GMT of IgA anti-EA was 780. These antibody titers were about 10 times lower than the corresponding GMT of the NPC patients investigated in this study. The elevated IgG and IgA antibody titers to VCA and EA in CLL and HCL patients seem to reflect an immunodeficiency secondary to the malignant disease leading to reactivation of latent EBV infection. The possibility that at least some of these B-cell lymphomas are associated with EBV cannot be excluded.     

Diagnostic Significance of Combined Detection of Epstein-Barr Virus Antibodies,VCA/IgA,EA/IgA,Rta/IgG and EBNA1/IgA for Nasopharyngeal Carcinoma

The objective of this study was to investigate the diagnostic significance of EBV antibody combined detectionfor nasopharyngeal carcinoma (NPC) in a high incidence region of southern China. Two hundred and elevenuntreated NPC patients, 203 non-NPC ENT patients, and 210 healthy controls were recruited for the study. Thetiters of VCA/IgA and EA/IgA were assessed by immunoenzyme assay, and the levels of Rta/IgG and EBNA1/IgAwere determined by enzyme-linked immunosorbent assay. The levels of VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA demonstrated no association with gender or age (p>0.05). The receiver operating characteristic curve andthe area under the curve were used to evaluate the diagnostic value. The sensitivity of VCA/IgA (98.1%) andthe specificity of EA/IgA (98.5%) were the highest. When a logistic regression model was used to combine theresults from multiple antibodies to increase the accuracy, the combination of VCA/IgA+Rta/IgG, whose areaunder the curve was 0.99, had the highest diagnostic efficiency, and its sensitivity, specificity and Youden indexwere 94.8%, 98.0% and 0.93 respectively. The data suggest that the combination of VCA/IgA+Rta/IgG may bemost suitable for NPC serodiagnosis.     

鼻咽癌患者发病前后EB病毒VCA/IgA和EA/IgA滴度动态分析

目的 观察鼻咽癌患者发病前后EB病毒VCA/IgA、EA／IgA滴度的变化规律,及其在鼻咽癌筛查中的作用。方法 收集中山市首次鼻咽癌筛查后12年VCA／IgA阳性人群中54例新发鼻咽癌患者发病前后的血清学资料,用免疫酶法检测EB病毒抗体VCA/IgA和EA／IgA。结果 确诊前1～7年VCA／IgA、EA／IgA总体呈上升趋势。发病前7～4年,VCA／IgA平均滴度在1：21．04上下波动,确诊前第3年起VCA／IgA急剧上升,确诊时几何平均滴度接近1：80,EA／IgA高较为缓慢,确诊时几何平均滴度为1：6．49。放疗后两种滴度均呈快速下降趋势,第4年起接近阳性人群的平均滴度。结论 多数鼻咽癌患者在确诊前3年,VCA／IgA滴度持续增高,但EA／IgA滴度增高缓慢;VCA／IgA可以检出早期鼻咽癌,但EA／IgA作用不大;鼻咽癌发展临床前期平均时间为3年。     

Detection of Epstein-Barr virus IgA/EA antibody for diagnosis of nasopharyngeal carcinoma by immunoautoradiography

An immunoautoradiographic method was used for the detection of EB virus IgA/EA antibody in sera from NPC patients and other control groups. Ninety-six percent of NPC patients had IgA/EA antibody with a high titer of GMT. The positive rates of IgA/EA antibody in patients with malignant tumours other than NPC and in normal individuals were only 4% and 0%, respectively. Eleven patients histologically diagnosed as having a chronic inflammation and who showed positive for IgA/EA antibody by immunoautoradiography were rebiopsied; six of them were discovered to have squamous cell carcinoma. Fourteen NPC patients had no IgA/EA antibody detected by immunofluorescence and immunoenzymatic testing, but 11 and six of them had IgA/VCA and IgA/EA antibodies detected by immunoautoradiography, respectively. These data indicate that the immunoautoradiographic method is more sensitive than either the immunofluorescence or immunoenzymatic test for the detection of IgA/EA antibody, and can be used for the detection of NPC in the early stages of development.     

提高EB病毒血清学在诊断鼻咽癌中的效益

目的 探讨同时应用VCA-IgA,EA-IgA和EA-IgG三项检测在血清学诊断鼻咽癌中的效益。方法 收集266例未经治疗的鼻咽癌患者和347例健康成人的血清,用免疫酶法检测VCA-IgA,用酶联免疫吸附法（ELISA）替代免疫酶法检测EA-IgA和EA-IgG抗体。应用新的统计学方法来评估这三项检测的不同优势比。结果 同时应用VCA-IgA,EA-IgG和EA-IgA三项检测的灵敏度和特异度分别为95.11%和97.41%。高于这三项检测的单独应用（VCA-IgA为90.60%和94.52%,EA-IgG为93.98%和93.66,EA-IgA为89.84%和88.18%）,再者,VCA-IgA,EA-IgG和EA-IgA三项检测均呈阳性者的优势比（1912.5)远远高于其中两项检测呈阳性者（VCA-IgA和EA-IgG为27.9032,EA-IgG和EA-IgA为11.1690;VCA-IgA和EA-IgA为8.0328)。而两项检测阳性的优势比又高于单个检测阳性者（VCA-IgA为0.1214;EA-IgG为0.1705;EA-IgA为0.0488)。结论 ELISA法较免疫酶法更能确切反映血清中EB病毒早期抗原的抗体水平。VCA-IgA,EA-IgG和EA-IgA的联合应用能显著提高灵敏度和特异度,明显增高检测阳性的优势比,因此,能有效地提高EB病毒血清学在诊断鼻咽癌时的效益。     

Neutralizing EBV-specific IgA in throat washings of nasopharyngeal carcinoma (NPC) patients.

Throat washings from 26 nasopharyngeal carcinoma (NPC) patients from Hong Kong and Tunisia were studied for the presence of transforming EBV. Only six (23%) were found positive which led to the hypothesis of a neutralizing factor in such salivas. The search for EBV-specific antibodies showed that NPC saliva contained neutralizing VCA and EA IgA (54 and 27% respectively) and VCA and EA IgG (73 AND 54% respectively). Both transforming and non-transforming throat washings contained virus particles as visualized by electron microscopy, but in non-transforming salivas (containing IgA and IgG) the particles were found to be clumped. Comparative study of throat washings from patients with Burkitt's lymphoma (BL); infectious mononucleosis (IM), immunodeficiencies, other cancers, and healthy subjects showed that IgA were restricted to NPC cases.     

以血清EB病毒抗体谱评估患鼻咽癌危险度的研究

目的：比较鼻咽癌患者与健康人群血清EB病毒抗体水平,评估患鼻咽癌的危险度。方法：收集珠江口地区121例鼻咽癌患者和332例健康人血清。采用酶联吸附试验（ELISA）检测血清中EBNA 1/IgA、EBNA 1／IgG和zta/IgG,以免疫酶法或免疫荧光法检测VCA／IgA。结果：EBNA 1／IgA、EBNA 1／IgG和zta/IgG的敏感度分别为85％、83％和79％;三者组合的敏感度最高,为92％。EBNA 1/IgA、EBNA 1／IgG和zta/IgG的特异度分别为86％、86％和80％;三者组合的特异度最高,为93％。根据优势比水平,可将患鼻咽癌的危险度分为低危险、中危险和高危险3个层次。93％的健康人是低危险的,优势比为0．0－0．3;0．4％的健康人是高危险的,优势比为137．9。结论：ELISA在诊断鼻咽癌的结果判断上更具客观性,较传统免疫酶法好;EBNA 1／IgA、EBNA 1／IgG和zta/IgG的联合应用可以评估人群患鼻咽癌的危险度。     

Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients.

Ninety-five sera from Chinese NPC patients in different stages of the disease, 38 sera from Chinese patients with other cancers, and 50 normal Chinese sera, were titrated for EBNA, VCA, EA and complement-fixing (CF/S) EBV-specific antibodies. The geometric mean (GMT) EBNA antibody titre of patients with NPC at stage I was found to be four times higher than that of normal individuals and increased in parallel with clinical deterioration. Antibody titres against EBNA did not correlate with either VCA or EA antibodies but, in general, correlated with CF/S antibodies. EA antibodies correlated relatively well with VCA antibodies and discriminated better than EBNA titre between NPC at stage I and controls.     

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA

Epstein–Barr virus (EBV) is closely associated with nasopharyngeal carcinoma (NPC). Serum IgA antibodies against early antigen (EA‐IgA) and viral capsid antigen (VCA‐IgA) are the most commonly used to screen for NPC in endemic areas. However, the prognostic value of serum EA‐IgA and VCA‐IgA in patients with NPC is less clear. We hypothesize that serum EA‐IgA and VCA‐IgA levels have prognostic impact for survival outcomes in NPC patients with undetectable pretreatment EBV (pEBV) DNA. In this series, 334 patients with non‐metastatic NPC and undetectable pEBV DNA were included. Serum EA‐IgA and VCA‐IgA were determined by ELISA. After analysis, serum EA‐IgA and VCA‐IgA loads correlated positively with T, N, and overall stage (all P < 0.05). Serum EA‐IgA was not associated with survival outcome in univariable analyses. But patients with serum VCA‐IgA >1:120 had significantly inferior 5‐year progression‐free survival (80.4% vs 89.6%, P = 0.025), distant metastasis‐free survival (88.4% vs 94.8%, P = 0.050), and locoregional relapse‐free survival (88.4% vs 95.6%, P = 0.023; log–rank test). Multivariable analyses revealed that N stage was the only independent prognostic factor (all P < 0.05), but the VCA‐IgA became insignificant. Further analyses revealed that serum VCA‐IgA was not an independent prognostic factor in early N (N0–1) or advanced N (N2–3) stage NPC. In summary, although both EA‐IgA and VCA‐IgA correlate strongly with TNM stage, our analyses do not suggest that these antibodies are prognostic biomarkers in patients with NPC and undetectable pEBV DNA.     

EB病毒抗体检测在不同年龄壮族鼻咽癌患者中的应用

目的探讨桂西地区壮族鼻咽癌患者EB病毒各年龄段Rta/IgG、VCA/IgA、VCA/IgG及Zta/IgG抗体的rA值和阳性率与年龄的关系。方法收集140 例未经治疗的鼻咽癌患者和280例健康人的血清,用酶联免疫吸附法（ELISA）检测Rta/IgG、VCA/IgA、VCA/IgG及Zta/IgG抗体,分别计算各年龄段的抗体水平及阳性率并进行统计学分析。结果鼻咽癌患者各年龄段VCA/IgA抗体rA值和阳性率差异均有统计学意义 (P<0.05)。在50岁以后年龄段的患者与健康人Rta/IgG、VCA/IgA抗体阳性率比较差异有统计学意义 (P<0.05)。在50岁以后的年龄段患者与健康人Zta/IgG抗体阳性率比较差异无统计学意义 (P>0.05)。结论壮族鼻咽癌患者与健康人EB病毒Rta/IgG、VCA/IgA及Zta/IgG抗体水平和阳性率比较存在年龄上的差异。在鼻咽癌的临床诊断和高危人群筛查中有必要根据不同年龄段的人群界定不同的阳性临界值。     

EB病毒VCA/IgA、Rta/IgG及EBNA1/IgA抗体水平在鼻咽癌高发区不同人群中的分布

目的 观察分析鼻咽癌高发区中的鼻咽癌患者、非鼻咽癌头颈部相似疾病患者和健康体检人群中EB病毒VCA/IgA、Rta/IgG及EBNA1/IgA的抗体水平分布情况。方法 收集211例未经治疗的鼻咽癌患者、203例头颈部相似症状患者和210例健康体检者的血清,采用免疫酶法检测VCA/IgA,采用酶联免疫吸附法（ELISA）检测Rta/IgG和EBNA1/IgA。应用秩和检验、受试者工作特征(ROC)曲线、多分类logistic回归模型等方法对结果进行分析评价。结果 鼻咽癌组的VCA/IgA、Rta/IgG及EBNA1/IgA抗体水平均显著高于头颈部相似疾病组和健康对照组(P<0.001)。头颈部相似疾病组的Rta/IgG及VCA/IgA抗体水平也明显高于健康对照组(P<0.001)。以头颈部相似疾病组和健康体检组为分析人群,分别作相关抗体的ROC曲线,VCA/IgA 的ROC曲线下面积为0.565,Rta/IgG抗体的ROC曲线下面积为0.604,具有统计学意义(P<0.05)。综合年龄、性别和3种EB病毒抗体等因素的多分类logistic回归分析显示,鼻咽癌、头颈部相似疾病和健康体检者的预测准确率分别为95.3％、70.9％和55.2％。结论 在鼻咽癌高发区EB病毒VCA/IgA及Rta/IgG抗体水平在头颈部相似疾病人群和健康人群中存在一定差异,在鼻咽癌的人群筛查和临床诊断中可根据具体情况设定不同的抗体阳性临界值。     

血浆 EB病毒游离 DNA检测对监测鼻咽癌患者预后的意义

背景与目的:有报道 , 测定血浆中的 EB病毒游离 DNA( EBV-DNA)的拷贝数可作为诊断及监测鼻咽癌患者病情变化的手段之一.本研究旨在评价血浆 EBV-DNA检测在鼻咽癌患者预后监测上的价值, 并进一步与 VCA/IgA、 EA/IgA进行比较.方法:比较鼻咽癌放疗后 30例远处转移患者、 22例局部复发患者、 24例无 瘤生存者血浆中 EBV-DNA、 VCA/IgA、 EA/IgA水平.分别应用荧光定量 PCR方法检测血浆 EBV-DNA水平,免疫酶法检测 VCA/IgA、 EA/IgA;前瞻性观察 20例初诊鼻咽癌患者放疗前、放疗剂量达 40 Gy时及放疗结束时上述指标的变化. 结果:放疗后各组不同预后患者的血浆 EBV-DNA含量的中位数有显著性差异, 远处转移组为 135 100 copies/ml(四分线区域 5 525～ 1 003 750 copies/ml) >局部复发组的 20 500(四分线区域 0～ 58 500 copies/ml) > 无瘤生存组的 0 copy/ml(四分线区域 0～ 0 copy/ml), P均 < 0.05. 远处转移组的血浆 EBV-DNA水平高者较多, 当阳性标准为 1 000 000 copies/ml时,诊断远处转移组的敏感性为 27.3%,而诊断局部复发组的敏感性为 0.0%,特异性均为 100.0%.在初诊患者放疗前、放疗剂量达 40 Gy时及放疗结束时, EBV-DNA水平逐渐降低,平均含量分别为 32 050 copies/ml(四分线区域 3 880～ 317 750 copies/ml)、 0 copy/ml(四分线区域 0～ 14 375 copies/ml)、 0 copy/ml(四分线区域 0～ 2 940 copies/ml), P均 < 0.05, 而 VCA/IgA、 EA/IgA的水平未见明显变化. 结论: 血浆 EBV-DNA检测可用于监测鼻咽癌患者预后,其价值明显优于 VCA/IgA、 EA/IgA.     

鼻咽癌病人Epstein-Barr病毒膜抗原抗体的检测

本文报道,用正丁酸和巴豆油激活人类类淋巴母细胞株—B95—8细胞株、诱导产生早期膜抗原(EMA)和晚期膜抗原(LMA),应用间接免疫荧光法检测鼻咽癌(NPC)病人血清中膜抗原(MA)抗体。MA/IgA在正常人阴性,而在NPC病人阳性率55.96％,GMT 1:20.1。经过葡萄球菌蛋白A(SPA)吸附病人血清后,能提高2～3个血清稀释度。对诊断NPC有意义。     

Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.

Stimulated by a report on elevated IgA levels in nasopharyngeal carcinoma (NPC), we tested a total of 372 sera from patients with NPC, other carcinomas of head and neck or elsewhere, Burkitt's lymphoma (BL), infectious mononucleosis (IM) or healthy controls. The sera were titrated in indirect immunofluorescence tests for IgA antibodies to Epstein-Barr virus (EBV) capsid antigen (VCA) and to the diffuse (D) or restricted (R) components of the EBV-induced early antigen (EA) complex. The results proved NPC to be outstanding in that prior to therapy 93% of the patients tested revealed IgA antibodies to VCA and 73% to D, often at high titers which occasionally matched the corresponding IgG antibody levels. The EBV-specific IgA titers increased from stages I or II to stages III or IV; i.e. with the total tumor burden. Conversely, many of the NPC patients examined 2-6 years after initial therapy had only low levels of EBV-specific IgA or none at all, and the majority of those with high titers were known to have residual or recurrent disease. In contrast to untreated NPC patients, less than 5% of 73 patients with other carcinomas or of 76 healthy donors revealed VCA-specific IgA and even fewer EA-specific IgA; only 28% and 4% of 54 BL patients tested at admission had IgA antibodies to VCA and R, respectively, and 38% and 3% of 37 IM patients showed transient VCA- or D-specific IgA responses, all at generally low titers. While sera from untreated NPC patients often contained IgA antibodies also to herpes simplex type 1 virus, their incidence and range of low titers were similar to those obtained with sera from patients with other carcinomas or from healthy donors. It thus appears that the elevated IgA levels in NPC might be due to EBV-specific antibodies. Possible reasons for this unique response in NPC have been discussed.     

Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma

Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) generally occurs in adults, especially in high-prevalence populations such as the Chinese and Eskimos. In Maghrebian populations, young patients affected with this malignancy represent 25% of the total NPC cases. In adults with NPC, relatively high titers of IgA antibodies to the EBV viral capsid antigen (VCA) and early antigen (EA) represent important markers. However, nearly 50% of young NPC patients are negative for IgA-anti-VCA and -EA or exhibit very low titers of these antibodies. We report here that 92% of sera from young NPC patients negative for IgA-EA and 89% of those negative for IgA-VCA were positive for IgG antibodies to the EBV transactivator protein (ZEBRA) at very high titers. Our results show that in young patients with NPC these antibodies represent the most reliable marker for diagnosis and prognosis, particularly when compared with conventional NPC markers, i.e., IgA-VCA (58%) and anti-EA (25%). The titers of IgG-ZEBRA antibodies increased along with lymph node involvement only in the young patient group, suggesting a prognostic value of this marker in this patient group.     

Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma

BACKGROUND: Serologic measurement of antibodies to Epstein-Barr virus (EBV) immunoglobulin A/viral capsid antigen (IgA/VCA) and early antigen (IgA/EA) has been used widely to screen for nasopharyngeal carcinoma (NPC) in China. Recently, it was found that plasma EBV DNA concentration is an indicator for the staging and prognosis of patients with NPC. To determine whether there is a correlation between plasma EBV DNA levels and serum levels of IgA/VCA, the authors measured both in patients with NPC and in a control group. METHODS: Real-time polymerase chain reaction was used for quantitative analysis of plasma EBV DNA concentration, and enzyme-linked immunoadsorbent assay was used to measure EBV VCA/IgA in patients with primary NPC (n = 120 patients), locally recurrent NPC (n = 8 patients), and distant metastatic NPC (n = 21 patients) among 76 patients with NPC after the completion of radiotherapy, in 60 patients with NPC in clinical remission, in 38 patients with non-NPC tumors, and in 47 control individuals. RESULTS: The median plasma EBV DNA levels were 6200 copies/mL, 9200 copies/mL, and 2050 copies/mL in patients with primary, locally recurrent, and distant metastatic NPC, respectively, but declined to 0 copies/mL in patients with clinically remissive NPC, in patients who completed radiotherapy, in patients with non-NPC tumors, and in the control group. In contrast, EBV VCA/IgA titers and detection rates remained high in all NPC groups. Plasma EBV DNA levels were significantly higher in patients who had serum VCA/IgA titers > or = 1:640 (median, 83,450 copies/mL) compared with the levels in patients who had titers < or = 1:320 (median, 17,200 copies/mL). Patients with NPC who had advanced TNM stage (Stages III and IV; median, 8530 copies/mL) and T classification (T3 and T4 tumors; median, 8530 copies/mL) had significantly higher plasma EBV DNA levels compared with patients who had early TNM stage (Stages I and II; median, 930 copies/mL) and T classification (T1 and T2 tumors; median, 3700 copies). Patients who had advanced TNM stage NPC had significantly higher mean VCA/IgA titers (1:424) compared with patients who had early TNM stage NPC (1:246), but there was no correlation between IgA/VCA titer and T or N classification of NPC. CONCLUSIONS: The results suggest that plasma EBV DNA detection is a more sensitive and specific marker than the serum IgA/VCA titer for the diagnosis and monitoring of patients with NPC. These findings provide convincing evidence for the use of plasma EBV DNA measurements for the early diagnosis and staging of NPC as well as for monitoring recurrence and metastasis of this tumor.     

ESTABLISHMENT OF HIGH RISK POPULATION AND PRECANCEROUS LESION OF NASOPHARYNGEAL CARCINOMA(NPC)

ＥＳＴＡＢＬＩＳＨＭＥＮＴＯＦＨＩＧＨＲＩＳＫＰＯＰＵＬＡＴＩＯＮＡＮＤＰＲＥＣＡＮＣＥＲＯＵＳＬＥＳＩＯＮＯＦＮＡＳＯＰＨＡＲＹＮＧＥＡＬＣＡＲＣＩＮＯＭＡ（ＮＰＣ）ＨｕａｎｇＴｅｎｇｂｏ１黄腾波ＷａｎｇＨｕｉｍｉｎ２汪慧民ＬｉＪｉｎｇｌｉａｎ３李...     

Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals

IgG and IgA antibodies to Epstein-Barr virus (EBV) membrane antigen (MA) were detected in sera from 96 NPC patients and normal individuals by the indirect immunofluorescence test. For MA/IgG antibody, 100% of NPC patients were positive with a GMT of 1:439.7 and 97.9% of normal individuals were positive with a GMT of 1:94.7. In contrast, for MA/IgA antibody, 58.3% of NPC patients were positive with a GMT of 1:7.3 and none of the normal individuals were positive. There was no difference in the detection of antibodies to EBV MA when other P3HR-1 or B95-8 cell lines, differing in their major membrane antigen, were used.     

自然人群413 164人鼻咽癌血清学普查

目的分析普查自然人群413 164人EB病毒壳抗原的免疫球蛋白A抗体(VCA-IgA)和早期抗原抗体(EA-IgA)阳性与性别、年龄及鼻咽癌检出关系.方法应用免疫酶法检测VCA-IgA和EA-IgA抗体,间接鼻咽镜检查,病理组织学诊断.结果普查自然人群413 164人检出VCA-IgA抗体阳性12 629人,阳性率3.06%,抗体阳性率高低与性别无关,与年龄高低呈正相关趋势.检出鼻咽癌174例,早期151例,早诊率86.78%,普查自然人群鼻咽癌检出率42.11/10万.鼻咽癌检出率高低与年龄呈正相关趋势.结论本法普查鼻咽癌可达提高早诊率目的,若普查重点能放在35岁以上人群意义更大.